Header

UZH-Logo

Maintenance Infos

Evaluation of the effect of short-term treatment with the integrase inhibitor raltegravir (Isentress TM) on the course of progressive feline leukemia virus infection


Bösch, Andrea Claudia. Evaluation of the effect of short-term treatment with the integrase inhibitor raltegravir (Isentress TM) on the course of progressive feline leukemia virus infection. 2012, University of Zurich, Vetsuisse Faculty.

Abstract

Cats progressively infected with the gammaretrovirus feline leukemia virus (FeLV) are at high risk to die within a few months to years due to several disease symptoms that range from immune suppression, to anemia and lymphoma/ leukemia. Up to now, there is no specific drug available to treat FeLV infection. In the present study an in vivo experiment was performed to investigate if a short-term treatment with the integrase inhibitor raltegravir can effectively suppress FeLV replication, allowing the immune system to overcome the infection and therefore progressively infected cats to turn to a latent status (regressive infection). After demonstrating the high tolerance of raltegravir in three healthy specified pathogen-free cats, seven progressively infected cats were treated during nine weeks (40 mg b.i.d. for 6.5 weeks and 80 mg b.i.d. for 2.5 weeks). A significant decrease in plasma viral RNA loads was observed, indicating the ability of raltegravir to reduce viral replication. However, a complete control of viremia was not achieved and only one cat showed a marginal antibody response against whole virus, which was probably insufficient to overcome the infection. Further investigations are needed to find an optimized treatment against FeLV, i.e. an ideal dosage, compound or combination of compounds has to be identified

Abstract

Cats progressively infected with the gammaretrovirus feline leukemia virus (FeLV) are at high risk to die within a few months to years due to several disease symptoms that range from immune suppression, to anemia and lymphoma/ leukemia. Up to now, there is no specific drug available to treat FeLV infection. In the present study an in vivo experiment was performed to investigate if a short-term treatment with the integrase inhibitor raltegravir can effectively suppress FeLV replication, allowing the immune system to overcome the infection and therefore progressively infected cats to turn to a latent status (regressive infection). After demonstrating the high tolerance of raltegravir in three healthy specified pathogen-free cats, seven progressively infected cats were treated during nine weeks (40 mg b.i.d. for 6.5 weeks and 80 mg b.i.d. for 2.5 weeks). A significant decrease in plasma viral RNA loads was observed, indicating the ability of raltegravir to reduce viral replication. However, a complete control of viremia was not achieved and only one cat showed a marginal antibody response against whole virus, which was probably insufficient to overcome the infection. Further investigations are needed to find an optimized treatment against FeLV, i.e. an ideal dosage, compound or combination of compounds has to be identified

Statistics

Downloads

253 downloads since deposited on 14 Feb 2013
85 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Dissertation
Referees:Lutz Hans, Fraefel Cornel
Communities & Collections:05 Vetsuisse Faculty > Veterinary Clinic > Department of Farm Animals
Dewey Decimal Classification:570 Life sciences; biology
630 Agriculture
Language:English
Date:August 2012
Deposited On:14 Feb 2013 07:10
Last Modified:05 Apr 2016 16:33
Related URLs:http://opac.nebis.ch/F/?local_base=EBI01&con_lng=GER&func=find-b&find_code=090&request=002087079

Download

Download PDF  'Evaluation of the effect of short-term treatment with the integrase inhibitor raltegravir (Isentress TM) on the course of progressive feline leukemia virus infection'.
Preview
Filetype: PDF
Size: 1MB